McGlashan, TH, Johannessen, JO. Early detection and intervention with schizophrenia: rationale. Schizophr Bull
1996; 22: 201–22.
Wyatt, RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull
1991; 17: 325–51.
Emsley, R, Oosthuizen, PP, Kidd, M, Koen, L, Niehaus, DJ, Turner, HJ. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J Clin Psychiatry
2006; 67: 1707–12.
Marshall, M, Lewis, S, Lockwood, A, Drake, R, Jones, P, Croudace, T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry
2005; 62: 975–83.
Perkins, D, Lieberman, J, Gu, H, Tohen, M, McEvoy, J, Green, A, et al. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry
2004; 185: 18–24.
Perkins, DO, Gu, H, Boteva, K, Lieberman, JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry
2005; 162: 1785–804.
Lieberman, JA, Tollefson, GD, Charles, C, Zipursky, R, Sharma, T, Kahn, RS, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry
2005; 62: 361–70.
Lieberman, JA, Bymaster, FP, Meltzer, HY, Deutch, AY, Duncan, GE, Marx, CE, et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev
2008; 60: 358–403.
Crespo-Facorro, B, Perez-Iglesias, R, Ramirez-Bonilla, M, Martinez-Garcia, O, Llorca, J, Vazquez-Barquero, JL. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J Clin Psychiatry
2006; 67: 1511–21.
Emsley, RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull
1999; 25: 721–9.
Moller, HJ, Riedel, M, Jager, M, Wickelmaier, F, Maier, W, Kuhn, KU, et al. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int J Neuropsychopharmacol
2008; 11: 985–97.
Lieberman, JA, Tollefson, G, Tohen, M, Green, AI, Gur, RE, Kahn, R, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry
2003; 160: 1396–404.
Sanger, TM, Lieberman, JA, Tohen, M, Grundy, S, Beasley, C Jr, Tollefson, GD. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry
1999; 156: 79–87.
Gaebel, W, Riesbeck, M, Wolwer, W, Klimke, A, Eickhoff, M, von Wilmsdorff, M, et al. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry
2007; 68: 1763–74.
Schooler, N, Rabinowitz, J, Davidson, M, Emsley, R, Harvey, PD, Kopala, L, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry
2005; 162: 947–53.
Green, AI, Lieberman, JA, Hamer, RM, Glick, ID, Gur, RE, Kahn, RS, et al. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res
2006; 86: 234–43.
Kahn, RS, Fleischhacker, WW, Boter, H, Davidson, M, Vergouwe, Y, Keet, IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet
2008; 371: 1085–97.
Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med
2005; 353: 1209–23.
Jones, PB, Barnes, TR, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry
2006; 63: 1079–87.
Kane, J, Honigfeld, G, Singer, J, Meltzer, H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry
1988; 45: 789–96.
Sikich, L, Frazier, JA, McClellan, J, Findling, RL, Vitiello, B, Ritz, L, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry
2008; 165: 1420–31.
Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet
2009; 373: 31–41.
Breier, A, Hamilton, SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry
1999; 45: 403–11.
Tollefson, GD, Birkett, MA, Kiesler, GM, Wood, AJ. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry
2001; 49: 52–63.
Lieberman, JA, Phillips, M, Gu, H, Stroup, S, Zhang, P, Kong, L, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology
2003; 28: 995–1003.
Phillips, MR, Xiong, W, Zhao, ZA. Issues Involved in the Use of Scales for the Assessment of Negative and Positive Symptoms in Psychotic Patients [in Chinese]. Hubei Science and Technology Publishing House, 1990.
First, MB, Spitzer, RL, Gibbon, M, Williams, JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). American Psychiatric Press, 1996.
Phillips, MR, Xiong, W, Wang, RW, Gao, YH, Wang, XQ, Zhang, NP. Reliability and validity of the Chinese versions of the Scales for Assessment of Positive and Negative Symptoms. Acta Psychiatr Scand
1991; 84: 364–70.
Guy, W. ECDEU Assessment Manual for Psychopharmacology. . National Institute for Mental Health, 1976.
Jones, SH, Thornicroft, G, Coffey, M, Dunn, G. A brief mental health outcome scale – reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry
1995; 166: 654–9.
Simpson, GM, Angus, JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl
1970; 212: 11–9.
Simpson, GM, Lee, JH, Zoubok, B, Gardos, G. A rating scale for tardive dyskinesia. Psychopharmacology (Berl)
1979; 64: 171–9.
Little, RJA, Rubin, DB. Statistical Analysis with Missing Data. John Wiley & Sons, 2002.
Agid, O, Remington, G, Kapur, S, Arenovich, T, Zipursky, RB. Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharmacol
2007; 27: 369–73.
Gitlin, M, Nuechterlein, K, Subotnik, KL, Ventura, J, Mintz, J, Fogelson, DL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry
2001; 158: 1835–42.
Robinson, D, Woerner, MG, Alvir, JM, Bilder, R, Goldman, R, Geisler, S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry
1999; 56: 241–7.
Szymanski, SR, Cannon, TD, Gallacher, F, Erwin, RJ, Gur, RE. Course of treatment response in first-episode and chronic schizophrenia. Am J Psychiatry
1996; 153: 519–25.
Lehman, AF, Lieberman, JA, Dixon, LB, McGlashan, TH, Miller, AL, Perkins, DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry
2004; 161: 1–56.
Penn, DL, Waldheter, EJ, Perkins, DO, Mueser, KT, Lieberman, JA. Psychosocial treatment for first-episode psychosis: a research update. Am J Psychiatry
2005; 162: 2220–32.
Kane, JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry
2004; 65 (suppl 9): 16–20.
Alvir, JM, Lieberman, JA, Safferman, AZ, Schwimmer, JL, Schaaf, JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med
1993; 329: 162–7.
Allison, DB, Mentore, JL, Heo, M, Chandler, LP, Cappelleri, JC, Infante, MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry
1999; 156: 1686–96.
Newcomer, JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007; 68 (suppl 4): 8–13.